Aytu BioPharma Inc. (NASDAQ:AYTU) Receives Consensus Recommendation of “Hold” from Brokerages

Aytu BioPharma Inc. (NASDAQ:AYTU) has been given a consensus recommendation of “Hold” by the five ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $9.3333.

A number of equities analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Tuesday, October 14th. Maxim Group lowered their target price on shares of Aytu BioPharma from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, September 25th. Wall Street Zen lowered Aytu BioPharma from a “buy” rating to a “hold” rating in a research note on Friday, September 26th. Ascendiant Capital Markets lifted their price objective on Aytu BioPharma from $12.50 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Finally, Zacks Research upgraded Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Monday, November 24th.

Aytu BioPharma Trading Down 3.2%

AYTU stock opened at $2.45 on Friday. Aytu BioPharma has a 52-week low of $0.95 and a 52-week high of $2.82. The company’s 50-day simple moving average is $2.23 and its 200-day simple moving average is $2.25. The firm has a market cap of $24.97 million, a P/E ratio of -0.80 and a beta of 0.28. The company has a quick ratio of 1.08, a current ratio of 1.23 and a debt-to-equity ratio of 0.45.

Aytu BioPharma (NASDAQ:AYTU) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Aytu BioPharma had a negative net margin of 20.52% and a positive return on equity of 17.86%. The business had revenue of $13.89 million during the quarter, compared to analyst estimates of $17.92 million.

Institutional Investors Weigh In On Aytu BioPharma

Institutional investors have recently added to or reduced their stakes in the company. Stonepine Capital Management LLC lifted its holdings in shares of Aytu BioPharma by 75.3% during the 2nd quarter. Stonepine Capital Management LLC now owns 812,676 shares of the company’s stock valued at $1,772,000 after acquiring an additional 348,955 shares in the last quarter. AWM Investment Company Inc. purchased a new stake in shares of Aytu BioPharma in the second quarter worth about $1,351,000. Kanen Wealth Management LLC acquired a new stake in shares of Aytu BioPharma in the second quarter valued at about $1,250,000. Two Sigma Investments LP grew its stake in shares of Aytu BioPharma by 96.2% in the third quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock valued at $129,000 after buying an additional 33,701 shares in the last quarter. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Aytu BioPharma during the 3rd quarter valued at about $117,000. Hedge funds and other institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.